Aura (AURA) COO Susan Abu‑Absi Receives RSU and Option Awards

What Happened

• Susan Abu‑Absi, Chief Operating Officer of Aura Biosciences (AURA), received equity awards on September 1, 2026 totaling 400,000 underlying shares: 134,513 restricted stock units (RSUs) and 265,487 derivative awards (options). Both were reported as acquired at $0.00 (typical for compensation/inducement grants).
• These are awards/inducements rather than purchases or sales, so they are compensation-related and will vest over time rather than representing immediate open‑market activity.

Key Details

• Transaction date: 2026-09-01; reported on Form 4 filed 2026-09-01 (timely).
• Award amounts: 134,513 RSUs (F1) + 265,487 derivative awards (F2) = 400,000 total underlying shares; price reported $0.00.
• Vesting (per footnotes):
  • RSUs (F1): Inducement RSU award; vests in four substantially equal annual installments, first tranche scheduled to vest on September 15, 2027, subject to continued service.
  • Derivative award/options (F2): 25% vest on August 10, 2027; remaining 75% vests pro rata in 36 monthly installments, subject to continued service.
• Shares owned after transaction: not specified in the provided filing details.
• No indication of immediate sale or cashless exercise; these awards will convert to owned shares only as they vest (and options only upon exercise if applicable).

Context

• These awards are compensation/inducement grants used to retain or incentivize an executive; they do not signal an immediate buy or sell in the open market. Vesting is service‑based, so the economic benefit depends on future continued employment and any exercise/strike terms for the derivative awards (exercise price not reported in the summary provided).